Anavex Life Sciences
NASDAQ: AVXLPortola Valley, US · 1 known investors
Anavex develops investigational oral therapies, including ANAVEX2-73 (blarcamesine), that target SIGMAR1 activation and autophagy to address neurodegenerative and neurodevelopmental diseases such as Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its drug candidates are in clinical trials.
BiotechHealthtech
Founders & leadership
SL
Sean LowryNamed on SEC filing
AV
Alexandre VamvakidesNamed on SEC filing
JC
John ChisholmNamed on SEC filing
HL
Harvey LalachNamed on SEC filing
GT
George TidmarshNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$10M disclosed across 2 rounds · 2012–2014
▶$10MraisedApr 2014 · 11 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher U. MisslingExecutive Officer, Director
- Athanosios SkarpelosDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $106.8K
- Sales commissions
- $700K
- Placement agents
- Maxim Group LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$10KraisedFeb 2012 · 1 investors · BiotechnologyRule 506(b)
▶$10KraisedFeb 2012 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean LowryDirector
- Alexandre VamvakidesExecutive Officer
- John ChisholmDirector
- Harvey LalachExecutive Officer, Director
- George TidmarshExecutive Officer, Director
- Offering amount
- $10K
- Amount sold
- $10K
- First sale
- Feb 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Anavex Life Sciences do?
- Anavex develops investigational oral therapies, including ANAVEX2-73 (blarcamesine), that target SIGMAR1 activation and autophagy to address neurodegenerative and neurodevelopmental diseases such as Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its drug candidates are in clinical trials.
- Who are Anavex Life Sciences's investors?
- Anavex Life Sciences's investors include Sofinnova Ventures.
- How much funding has Anavex Life Sciences raised?
- Anavex Life Sciences has disclosed $10M raised across 2 rounds.
- Where is Anavex Life Sciences headquartered?
- Anavex Life Sciences is headquartered in Portola Valley, US.